Financial Services » Investing & Securities | Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
16.96 M
Public Float
12.45 M
Cellular Biomedicine Group Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.24
Market Cap
$274.98 M
Shares Outstanding
19.23 M
Public Float
11.1 M

Profile

Address
1345 Avenue of Americas
New York New York 10105
United States
Employees -
Website http://www.cellbiomedgroup.com
Updated 07/08/2019
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA. .

Financials

View All

Bi Zuo Liu
CEO, Chief Financial Officer Director
Bosun S. Hau
Non-Executive Director